A randomised phase 2 study of Panitumumab Monotherapy and Panitumumab Plus 5 Fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer. MONARCC
- Segelov, Eva (Primary Chief Investigator (PCI))
Project: Research
Project: Research